As you can see from our front page this month, Compliance Week recently hosted another editorial roundtable—this time looking particularly at compliance challenges in the life sciences sector. We don’t usually do that; every industry has its own unique compliance burdens that don’t carry much significance for other industries, and in a sector as highly regulated as the drug business, you’d expect that isolation to be especially so.
